Rhinomed (ASX:RNO) ROCE % : 0.00% (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rhinomed's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.

Rhinomed ROCE % Historical Data

The historical data trend for Rhinomed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed ROCE % Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-127.12

-100.02

-103.76

-100.04

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-80.59	-147.68	-90.58	-320.83	-

Rhinomed ROCE % Calculation

Rhinomed's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-10.614	/	( ( (8.498 - 3.195)	+	(3.075 - 9.381) )	/ 2 )
	=	-10.614	/	( (5.303	+	-6.306)	/ 2 )
	=	-10.614	/	-0.5015
	=	2,116.45 %

Rhinomed's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-12.062	/	( ( (9.259 - 8.848)	+	(3.075 - 9.381) )	/ 2 )
	=	-12.062	/	( ( 0.411	+	-6.306 )	/ 2 )
	=	-12.062	/	-2.9475
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Rhinomed (ASX:RNO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rhinomed ROCE % Related Terms

Thank you for viewing the detailed overview of Rhinomed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines